No LIGHT shed on CV safety of naltrexone-bupropion
The cardiovascular risks of the weight-loss combination drug naltrexone-bupropion are still uncertain, because the FDA-mandated safety trial, LIGHT, was terminated prematurely due to the sponsoring...
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news
More News: Bupropion | Cardiology | Cardiovascular | Endocrinology | Heart | Weight Loss | Wellbutrin